Veracyte, Inc.

198 articles with Veracyte, Inc.

• Veracyte to Present at the Canaccord Genuity 38th Annual Growth Conference

  7/30/2018

  Veracyte, Inc. announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the Canaccord Genuity 38th Annual Growth Conference on Thursday, August 9, 2018 at 11:30 a.m. Eastern Time in Boston.

• Veracyte Announces Pricing of Public Offering of 5,000,000 Shares of Common Stock At $10.25 Per Share

  7/26/2018

  Veracyte, Inc. announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $10.25 per share.

• Veracyte Announces Second Quarter 2018 Financial Results

  7/23/2018

  Revenue up 24% to $22.8 Million Compared to Second Quarter 2017

• Veracyte to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results on Monday, July 23, 2018

  7/9/2018

  Veracyte, Inc. announced today that it will report its second quarter 2018 financial results after the close of market on Monday, July 23, 2018.

• Veracyte Chairman and CEO to Speak at MedCity CONVERGE

  7/2/2018

  ​Veracyte, Inc. today announced that Bonnie Anderson, chairman and chief executive officer, will speak at the 2018 MedCity CONVERGE conference in a session entitled, “Early Diagnosis Through Predictive Biomarkers, Noninvasive Testing.”

• Veracyte to Present at the William Blair 38th Annual Growth Stock Conference

  5/30/2018

  Veracyte, Inc. announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the William Blair 38th Annual Growth Stock Conference.

• Veracyte Announces New Study Published in JAMA Surgery Demonstrates Afirma GSC’s Ability to Significantly Reduce Unnecessary Surgeries in Thyroid Cancer Diagnosis

  5/23/2018

  Veracyte, Inc. announced that clinical validation data published for the first time today – in JAMA Surgery – demonstrate that the next-generation Afirma Genomic Sequencing Classifier (GSC) identifies at least one third more benign thyroid nodules among those deemed indeterminate by cytopathology, as compared to the original, market-leading Afirma test.

• Veracyte to Launch New Afirma Xpression Atlas and Present Platform Performance Data at AACE 2018 Meeting

  5/10/2018

  Multiple Abstracts Showcasing “Real-World” Performance of the Afirma Genomic Sequencing Classifier also to be Presented

• Veracyte Announces First Quarter 2018 Financial Results

  5/1/2018

  Veracyte, Inc. announced financial results for the first quarter ended March 31, 2018 and provided an update on recent business progress.

• Veracyte Announces Precision Medicine Collaboration With Loxo Oncology

  4/11/2018

  Agreement Leverages Veracyte’s New Afirma Xpression Atlas Platform

• Veracyte Unveils Afirma Xpression Atlas Platform at ENDO 2018

  3/19/2018

  Veracyte, Inc. announced that its soon-to-be-launched Afirma Xpression Atlas platform was unveiled at ENDO 2018, the annual meeting of the Endocrine Society, being held March 17-20 in Chicago.

• Veracyte Announces New Data Demonstrating “Real-World” Performance of Afirma GSC To Be Presented at ENDO 2018

  3/14/2018

  Company to Unveil New Afirma Xpression Atlas Platform

• Veracyte Announces Fourth Quarter and Full-Year 2017 Financial Results, Provides 2018 Financial Outlook

  2/27/2018

  Veracyte, Inc. announced financial results and business progress for the quarter and full year ended December 31, 2017, and provided financial guidance for 2018.

• Veracyte to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2017 Financial Results on Tuesday, February 27, 2018

  2/12/2018

  Following the announcement, Veracyte will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the company's financial results and provide a general business update.

• Veracyte Announces 100,000th Afirma Test Performed to Reduce Unnecessary Surgeries in Thyroid Cancer Diagnosis

  1/25/2018

  During National Thyroid Awareness Month in January, Veracyte, Inc. announced that to date it has performed 100,000 Afirma genomic tests to help reduce unnecessary surgeries in patients being evaluated for potential thyroid cancer.

• Veracyte’s Chief Science and Medical Officer to Present at The Precision Medicine World Conference

  1/19/2018

  The PMWC is being held January 22-24 at the Computer History Museum in Mountain View, Calif.

• 

  Pfizer Quits Neuroscience R&D

  1/8/2018

  As a result, the company will cut 300 jobs, primarily in Massachusetts and Connecticut.
• 

  Bay Area's Veracyte to Consolidate R&D Into One Department in Realignment

  1/8/2018

  Not only has the company made changes to its R&D division, it is strengthening its sales division as well.

• Veracyte Announces Publication of Data Confirming Analytical Validity of Envisia Genomic Classifier for Use in IPF Diagnosis

  11/28/2017

  The findings add to the growing body of evidence, including previously reported clinical validity and clinical utility data, supporting the use of the Envisia classifier to enable diagnosis of IPF, without the need for invasive, risky and costly surgical procedures.

• Veracyte Announces New Clinical Utility Data Suggesting Envisia Genomic Classifier Enables as Confident a Diagnosis in IPF as Surgical Pathology

  11/10/2017

  The new data were shared during the Pulmonary Fibrosis Foundation’s biannual PFF Summit, being held November 9-11 in Nashville, Tenn.